Cocrystal Pharma (NASDAQ:COCP – Get Free Report) had its price target reduced by equities researchers at HC Wainwright from $7.00 to $6.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 302.68% from the stock’s previous close.
Cocrystal Pharma Stock Down 3.9%
Shares of NASDAQ:COCP opened at $1.49 on Friday. Cocrystal Pharma has a twelve month low of $1.12 and a twelve month high of $3.26. The stock’s 50 day moving average is $1.51 and its 200-day moving average is $1.75.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.29. Equities analysts anticipate that Cocrystal Pharma will post -1.85 EPS for the current fiscal year.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Read More
- Five stocks we like better than Cocrystal Pharma
- What is Short Interest? How to Use It
- GE Aerospace Turns Engines Into Long-Term Profits
- How to Invest in the FAANG Stocks
- Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes
- What is the NASDAQ Stock Exchange?
- Marvell’s New AI Chip Deals Capture Wall Street’s Attention
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
